Added: Cherrish Romo - Date: 17.02.2022 02:23 - Views: 37935 - Clicks: 2113
Patients recently exposed to opioids are expected to be more sensitive to the effects of alvimopan and therefore may experience abdominal pain, nausea and vomiting, and diarrhea. No ificant interaction is expected with concurrent use of opioid analgesics and alvimopan in patients who received opioid analgesics for 7 or fewer consecutive days prior to alvimopan. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered.
Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for s of respiratory depression and sedation. Bremelanotide may slow gastric emptying and potentially reduces the rate and extent of absorption of concomitantly administered oral medications. Avoid use when taking any oral drug that is dependent on threshold concentrations for efficacy.
Interactions listed are representative examples and do not include all possible clinical examples. Other see comment. Either increases effects of the other by pharmacodynamic synergism. Coadministration enhances CNS depressant effects.
Avoid coadministration with other drugs that cause constipation. Increases risk for constipation related serious adverse reactions. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling.
Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d. If drug combination must be administered, monitor for evidence of serotonergic or opioid-related toxicities. Either increases effects of the other by Other see comment. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis.
Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use. Applies only to oral form of both agents. Co-administration of opioid agonists delay and reduce absorption of prasugrel and its active metabolite presumably by slowing gastric emptying; consider the use of a parenteral anti-platelet agent in acute coronary syndrome patients requiring co-administration of opioid agonists.
Do not use within 14 days of MAOI use. Risk of hypotension, hyperpyrexia, somnolence, or death. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.
Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Co-administration of opioid agonists delay and reduce absorption of ticagrelor and its active metabolite presumably by slowing gastric emptying; consider the use of a parenteral anti-platelet agent in acute coronary syndrome patients requiring co-administration of opioid agonists.
Comment: Tramadol may reinitiate opiate dependence in pts. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate. Effect of interaction is not clear, use caution. Prevents conversion of codeine to its active metabolite morphine. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death.
Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate. Prevents the conversion of codeine to its active metabolite morphine. Comment: Concomitant administration can increase the potential for CNS effects e.
Opioids may decrease MAC requirements, less inhalation anesthetic may be required. Either increases toxicity of the other by sedation. Adjust dose of drugs that are CYP2D6 substrates as necessary. Risk for sedation increased if flibanserin is coadministration with other CNS depressants. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
Either increases effects of the other by sedation. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects. Either increases toxicity of the other by Other see comment. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.
Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate. Continuously monitor vital s during sedation and recovery period if coadministered. Rolapitant may increase plasma concentrations of CYP2D6 substrates for at least 28 days following rolapitant administration. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.
Dosage adjustments of suvorexant and concomitant CNS depressants may be necessary. Assess need to reduce dose of CYP2D6-metabolized drug. Increased CNS depression.
Decreased conversion of codeine to active metabolite morphine. Risk of increased CNS depression. Mechanism: unspecified interaction mechanism. Additive decreased GI motility. Additive analgesia. Ziconotide does NOT potentiate opioid induced respiratory depression. Monitor Closely 1 abiraterone increases levels of codeine by affecting hepatic enzyme CYP2D6 metabolism. Monitor Closely 1 codeine increases and albuterol decreases sedation.
Monitor Closely 1 alfentanil and codeine both increase sedation. Monitor Closely 1 alprazolam and codeine both increase sedation. Contraindicated 1 alvimopan, codeine. Monitor Closely 1 amiodarone will increase the level or effect of codeine by affecting hepatic enzyme CYP2D6 metabolism. Monitor Closely 1 codeine and amitriptyline both increase sedation.
Monitor Closely 1 amobarbital and codeine both increase sedation. Monitor Closely 1 codeine and amoxapine both increase sedation. Monitor Closely 1 codeine and apomorphine both increase sedation. Monitor Closely 1 codeine increases and arformoterol decreases sedation. Monitor Closely 1 codeine and aripiprazole both increase sedation. Monitor Closely 1 codeine increases and armodafinil decreases sedation. Minor 1 asenapine will increase the level or effect of codeine by affecting hepatic enzyme CYP2D6 metabolism.
Monitor Closely 1 azelastine and codeine both increase sedation. Monitor Closely 1 baclofen and codeine both increase sedation.Codeine and side effects
email: [email protected] - phone:(471) 398-7405 x 3577
Codeine Phosphate Tablets 30mg